This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cropp, C. S. Articles by Callahan, R. Search for Related Content PubMed PubMed Citation Articles by Cropp, C. S. Articles by Callahan, R.

Identification of Three Regions on Chromosome 17q in Primary Human Breast Carcinomas Which Are Frequently Deleted¹

Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 [C. C., R. C.], and INSERM, Centre Rene Huguenin, 92211 Saint Cloud, France [M. H. C., R. L.]

² To whom requests for reprints should be addressed, at National Cancer Institute, Building 10, Room 5B50, Bethesda, MD 20892.

We have examined the long arm of chromosome 17 in sporadic breast carcinomas for the loss of heterozygosity (LOH) at 18 polymorphic loci. At least three distinct regions could be identified by the frequency of LOH and confirmed by high density deletion maps of individual tumor DNAs. A proximal region affected by LOH is located in a 22-cM region defined by D17S73 and NME1 and thus is similar in location to the region thought to contain the BRCA1 gene associated with familial breast and breast/ovarian cancer. The central region affected by LOH is bordered by the D17S86 and D17S21 loci and is estimated to be 28 cM in size. The third region is bordered by the D17S20 and D17S77 loci which are 11 cM apart. These results define three independent regions of chromosome 17q which are likely to contain tumor suppressor genes relevant to the etiology of sporadic breast carcinoma.

¹ Supported by the Ligue Nationale de Lutte Contre le Cancer; the Comites Regionaux des Hauts de Seine, du Val d'Oise et des Yvelines; and Association pour la Recherche sur le Cancer.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 9/ 7/93. Accepted 10/20/93.

This article has been cited by other articles:

				G. R. Bean, C. Ibarra Drendall, V. K. Goldenberg, J. C. Baker Jr., M. M. Troch, C. Paisie, L. G. Wilke, L. Yee, P. K. Marcom, B. F. Kimler, et al. Hypermethylation of the Breast Cancer-Associated Gene 1 Promoter Does Not Predict Cytologic Atypia or Correlate with Surrogate End Points of Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 50 - 56. [Abstract] [Full Text] [PDF]

				K.-A. Phillips Immunophenotypic and Pathologic Differences Between BRCA1 and BRCA2 Hereditary Breast Cancers J. Clin. Oncol., November 1, 2000; 18(90001): 107s - 112. [Abstract] [Full Text] [PDF]

				X. Cui, H. Feiner, Z. Lin, and H. Li Multiplex Genotype Analysis of Invasive Carcinoma and Accompanying Proliferative Lesions Microdissected from Breast Tissue J. Mol. Diagn., February 1, 2000; 2(1): 29 - 36. [Abstract] [Full Text]

				A. A. Thompson, J. A. Talley, H. N. Do, H. L. Kagan, L. Kunkel, J. Berenson, M. D. Cooper, A. Saxon, and R. Wall Aberrations of the B-Cell Receptor B29 (CD79b) Gene in Chronic Lymphocytic Leukemia Blood, August 15, 1997; 90(4): 1387 - 1394. [Abstract] [Full Text] [PDF]

				T M Smith, M K Lee, C I Szabo, N Jerome, M McEuen, M Taylor, L Hood, and M C King Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res., November 1, 1996; 6(11): 1029 - 1049. [Abstract] [PDF]

				P. Futreal, Q Liu, D Shattuck-Eidens, C Cochran, K Harshman, S Tavtigian, L. Bennett, A Haugen-Strano, J Swensen, Y Miki, et al. BRCA1 mutations in primary breast and ovarian carcinomas Science, October 7, 1994; 266(5182): 120 - 122. [Abstract] [PDF]